# Bioequivalence Study of Azilsartan Medoxomil 80 mg Tablets (Gedeon Richter Plc., Hungary) and Edarbi® 80 mg Tablets (JSC Nizhpharm, Russia)

> **NCT06990204** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Gedeon Richter Plc.** · enrollment: 56 (estimated)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Azilsartan medoxomil 80 mg tablet
- **DRUG:** Edarbi® 80 mg tablets

## Key facts

- **NCT ID:** NCT06990204
- **Lead sponsor:** Gedeon Richter Plc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-06
- **Primary completion:** 2025-07-01
- **Final completion:** 2025-07-01
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06990204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06990204, "Bioequivalence Study of Azilsartan Medoxomil 80 mg Tablets (Gedeon Richter Plc., Hungary) and Edarbi® 80 mg Tablets (JSC Nizhpharm, Russia)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06990204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*